Navigation Links
BioGenex and Abbott Molecular Conclude Successful Partnership
Date:3/4/2013

FREMONT, Calif., March 4, 2013 /PRNewswire/ -- After a long and successful collaboration and partnership, BioGenex and Abbott Molecular have announced that BioGenex will take over direct sales and support responsibility for co-branded Xmatrx instruments, auto FISH reagents and consumables, with immediate effect.

Xmatrx FISH, the product of successful partnership, enabled walk-away automation of all assay steps required to perform Abbott's FISH tests from baking to final cover slip, providing ready-to-view slides.

BioGenex will support current Xmatrx customers, and if desired by the customers, will enable their Xmatrx system to perform other slide based assays e.g. IHC, ISH, SS, and miRNA in addition to FISH.

"Abbott and BioGenex are working closely and are committed to ensure seamless transition. Hospitals, labs, and research institutions that use Xmatrx can be assured that they will get best in class service and support. BioGenex and Abbott representatives have jointly advised the customers of this change. "The transition to the next phase of our relationship is a testament to the truly unique capabilities of the Xmatrx platform, which allows automation of molecular pathology staining assays, from microtome to microscope," said Dr. Krishan Kalra , CEO, BioGenex.

About Xmatrx® ELITE
Xmatrx® ELITE is an integrated system consisting of a platform technology for full automation for any slide based assay e.g. IHC, ISH, SS, miRNA & FISH. This truly All-in-One fully automated system from microtome to microscope maximizes the testing capacity, minimizes hands-on time, and ensures consistent and quality results every time.

Xmatrx® ELITE enabled with specially formulated and optimized reagents, including primary antibodies, nucleic acid probes, special stains, detection kits and consumables delivers optimum performance yet is cost effective for total automation. This underlies our commitment to provide flexible work flow solutions for today, tomorrow and beyond.

About us [www.biogenex.com]
BioGenex designs, develops, and commercializes advanced fully-automated Molecular Diagnostic Systems for cancer diagnosis, prognosis, therapy selection, personalized medicine, and life science research. Our products include fully automated instruments, Nucleic Acid probes, Antibodies, detection systems, ancillary reagents, and consumables to provide the total solution for ISH, CISH, IHC, SS, FISH, and in Situ PCR. Our customer focused approach, with premier after-sales support and excellent technical service, provides the best-in-class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest reagents and instruments for life Science research and diagnostics.

Visit BioGenex @ USCAP 2013 | Booth No. 130 | Mar.04-Mon to Mar.06-Wed, 2013 | Baltimore Convention Center | USA

Media Contact:

Saba Ammari, 5108241400, s.ammari@biogenex.com

USA Office: T: +1-510-824-1400 | F: +1-510-824-1490 | Toll Free: 1-[800] 421-4149 | 49026 Milmont Drive Fremont CA 94538 | U.S.A.

India Office : T: +91-40-27185500 | F: +91-40-27185511/21 | 225 Cherlapally - Industrial Development Area - Phase II Hyderabad, AP | India 500051


'/>"/>
SOURCE BioGenex
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis Announces Exclusive Distribution Agreement with Abbott
2. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
3. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
4. Abbott, The Abbott Fund And Direct Relief International Reach Key HIV Testing Milestones: 20 Million Tests Provided Over 10 Years, And More Than 150,000 HIV Cases Prevented In Children
5. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
6. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
7. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
8. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
9. Global Market for Molecular Diagnostics to Exceed $10.7 Billion by 2018, Regenerative Medicine to Top $4.4 Billion
10. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
11. DioGenix and Fast Forward Collaborate to Develop Blood-Based Molecular Diagnostic for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):